Skip to main content

Hyperpigmentation

0
Pipeline Programs
3
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

ReVision Therapeutics
ReVision TherapeuticsNJ - Ridgewood
3 programs
Brightening TreatmentN/A1 trial
Cosmetic dark spot corrector serumN/A1 trial
Gentle Cleansing Lotion, Revision SkincareN/A1 trial
Active Trials
NCT07501000Completed11Est. Jan 2025
NCT07468175Completed48Est. Mar 2025
NCT05423873Completed33Est. Feb 2022
Zywie
ZywieNJ - Princeton
1 program
Oziva Bioactive Gluta Fizzy Effervescent Tablets 4.1 g containing GlutathioneN/A1 trial
Active Trials
NCT07162623Active Not Recruiting60Est. Apr 2026
DermBiont
DermBiontMA - Boston
1 program
DBI-102PHASE_21 trial
Active Trials
NCT05511948Completed75Est. Mar 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
DermBiontDBI-102
ZywieOziva Bioactive Gluta Fizzy Effervescent Tablets 4.1 g containing Glutathione
ReVision TherapeuticsCosmetic dark spot corrector serum
ReVision TherapeuticsBrightening Treatment
ReVision TherapeuticsGentle Cleansing Lotion, Revision Skincare

Clinical Trials (5)

Total enrollment: 227 patients across 5 trials

Randomized and Open Label Study for Safety and Efficacy of DBI-102 vs. Vehicle vs. Hydroquinone on Skin Pigmentation and Lentigos

Start: Aug 2022Est. completion: Mar 202375 patients
Phase 2Completed
NCT07162623ZywieOziva Bioactive Gluta Fizzy Effervescent Tablets 4.1 g containing Glutathione

Clinical Study to Assess Safety, Efficacy and In-Use Tolerability of Oziva Bioactive Gluta Fizzy Effervescent Tablets on Subjects With Facial Dark Spots Such as Pimple Marks, Sunspots, Age Spots and Uneven Skin Tone

Start: Sep 2025Est. completion: Apr 202660 patients
N/AActive Not Recruiting
NCT07468175ReVision TherapeuticsCosmetic dark spot corrector serum

A 16-week Clinical Study Investigating a Dark Spot Corrector Serum in Women With Moderate Discrete Hyperpigmentation

Start: Oct 2024Est. completion: Mar 202548 patients
N/ACompleted

Evaluation of the Safety and Tolerability of a Brightening Treatment Paired With a Skincare Regimen

Start: Oct 2024Est. completion: Jan 202511 patients
N/ACompleted
NCT05423873ReVision TherapeuticsGentle Cleansing Lotion, Revision Skincare

A Multi-Center, Open-label Study Evaluate the Efficacy and Tolerability of a Dual Skincare Regimen Treatment for Facial Hyperpigmentation and Photodamaged Skin in Patients Exposed to Extrinsic Factors of Aging

Start: Mar 2021Est. completion: Feb 202233 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.